The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The U.S. Food and Drug Administration (FDA) approved Optune Pax, a portable, noninvasive device for the...
The FDA has approved daratumumab and hyaluronidase-fihj in combination with other therapies as first-line treatment for certain patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro)...
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug Administration (FDA) has approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection as an alternative...
The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval to rucaparib (Rubraca)...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma (MZL)...
Pirtobrutinib was approved for certain relapsed/refractory chronic lymphocytic leukemias or small lymphocytic lymphomas. The U.S. Food and Drug Administration (FDA) has granted traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory chronic...
Durvalumab was approved as neoadjuvant and adjuvant treatment with chemotherapy for resectable gastric or gastroesophageal junction cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) as a neoadjuvant and adjuvant therapy...
The combination therapy is approved for pre- and post-surgery bladder cancer treatment. The U.S. Food and Drug Administration (FDA) has approved a combination therapy that uses either pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More